Lv51
1140 积分 2023-05-06 加入
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies
2小时前
待确认
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity
2小时前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
6小时前
已完结
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China
1个月前
已完结
Cluster headache
2个月前
已完结
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
2个月前
已完结
Pharmacokinetics and Safety of Lu AG09222, an Anti-PACAP Monoclonal Antibody in Development for Migraine Prevention (P10-15.015)
2个月前
已关闭
The pipeline and market for migraine drugs
2个月前
已完结
Bispecific nanobodies – promising engineered candidates with high therapeutic efficiency
3个月前
已完结
皖公网安备34019202002308
